Swedish Orphan Bio Spon (SWTUY) Cut to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of Swedish Orphan Bio Spon (NASDAQ:SWTUY) from a buy rating to a hold rating in a research report released on Thursday.

According to Zacks, “Swedish Orphan Biovitrum AB is a biopharmaceutical company which develops and makes drugs for patients with rare diseases. Its product portfolio primarily includes Kineret within the inflammation therapeutic area, Orfadin, Ammonaps and Ammonul within the genetics and metabolic therapeutic which are in clinical trial stage. Swedish Orphan Biovitrum AB is headquartered in Stockholm, Sweden. “

Shares of Swedish Orphan Bio Spon (SWTUY) opened at 15.72 on Thursday. Swedish Orphan Bio Spon has a 12-month low of $10.25 and a 12-month high of $16.49. The firm has a market capitalization of $4.23 billion and a PE ratio of 54.21. The company has a 50-day moving average price of $15.72 and a 200 day moving average price of $15.04.

COPYRIGHT VIOLATION NOTICE: This report was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.themarketsdaily.com/2017/09/10/swedish-orphan-bio-spon-swtuy-cut-to-hold-at-zacks-investment-research.html.

Get a free copy of the Zacks research report on Swedish Orphan Bio Spon (SWTUY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Swedish Orphan Bio Spon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Bio Spon and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply